Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 20,129 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 20,129 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.51, for a total value of $835,554.79. Following the transaction, the director owned 12,546 shares in the company, valued at approximately $520,784.46. The trade was a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA opened at $41.65 on Thursday. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $42.98. The firm has a market cap of $3.16 billion, a PE ratio of 92.52 and a beta of 0.02. The business has a 50 day moving average price of $40.03 and a 200-day moving average price of $34.79.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The company’s quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.18) EPS. Research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at approximately $1,180,000. Castleark Management LLC purchased a new stake in Kiniksa Pharmaceuticals International during the third quarter worth $6,160,000. PharVision Advisers LLC bought a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at about $261,000. Voleon Capital Management LP purchased a new position in shares of Kiniksa Pharmaceuticals International in the 3rd quarter worth approximately $3,462,000. Finally, Prosperity Wealth Management Inc. purchased a new position in Kiniksa Pharmaceuticals International in the third quarter worth $540,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. The Goldman Sachs Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Citigroup upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.